Savitskaya Yulia A, Rico-Martínez Genaro, Linares-González Luis Miguel, Delgado-Cedillo Ernesto Andrés, Téllez-Gastelum René, Alfaro-Rodríguez Alfonso Benito, Redón-Tavera Antonio, Ibarra-Ponce de León José Clemente
Tissue Engineering, Cell Therapy and Regenerative Medicine Unit, National Institute of Rehabilitation, Calzada México Xochimilco 289, Colonia Arenal de Guadalupe, Delegación Tlalpan, México, D,F,, México, Código Postal 14389.
Clin Sarcoma Res. 2012 Mar 23;2:9. doi: 10.1186/2045-3329-2-9.
Osteosarcoma is the most common primary high-grade bone tumor in both adolescents and children. Early tumor detection is key to ensuring effective treatment. Serum marker discovery and validation for pediatric osteosarcoma has accelerated in recent years, coincident with an evolving understanding of molecules and their complex interactions, and the compelling need for improved pediatric osteosarcoma outcome measures in clinical trials. This review gives a short overview of serological markers for pediatric osteosarcoma, and highlights advances in pediatric osteosarcoma-related marker research within the past year. Studies in the past year involving serum markers in patients with pediatric osteosarcoma can be assigned to one of four categories, i.e., new approaches and new markers, exploratory studies in specialized disease subsets, large cross-sectional validation studies, and longitudinal studies, with and without an intervention.Most of the studies have examined the association of a serum marker with some aspect of the natural history of pediatric osteosarcoma. As illustrated by the many studies reviewed, several serum markers are emerging that show a credible association with disease modification. The expanding pool of informative osteosarcoma-related markers is expected to impact development of therapeutics for pediatric osteosarcoma positively and, it is hoped, ultimately clinical care. Combinations of serum markers of natural immunity, thyroid hormone homeostasis, and bone tumorigenesis may be undertaken together in patients with pediatric osteosarcoma. These serum markers in combination may do better. The potential effect of an intrinsic dynamic balance of tumor angiogenesis residing within a single hormone (tri-iodothyronine) is an attractive concept for regulation of vascularization in pediatric osteosarcoma.
骨肉瘤是青少年和儿童中最常见的原发性高级别骨肿瘤。早期肿瘤检测是确保有效治疗的关键。近年来，随着对分子及其复杂相互作用的认识不断发展，以及在临床试验中迫切需要改进儿童骨肉瘤的疗效评估指标，儿童骨肉瘤血清标志物的发现和验证工作加速推进。本综述简要概述了儿童骨肉瘤的血清学标志物，并重点介绍了过去一年中儿童骨肉瘤相关标志物研究的进展。过去一年中涉及儿童骨肉瘤患者血清标志物的研究可分为四类，即新方法和新标志物、特定疾病亚组的探索性研究、大型横断面验证研究以及有或无干预的纵向研究。大多数研究都考察了血清标志物与儿童骨肉瘤自然病程某些方面的关联。正如众多综述研究所表明的，一些血清标志物正在出现，它们与疾病改变显示出可信的关联。越来越多与骨肉瘤相关的信息丰富的标志物有望对儿童骨肉瘤治疗方法的开发产生积极影响，并最终有望改善临床护理。儿童骨肉瘤患者可能会同时检测天然免疫、甲状腺激素稳态和骨肿瘤发生的血清标志物组合。这些血清标志物组合可能效果更好。单一激素（三碘甲状腺原氨酸）内肿瘤血管生成的内在动态平衡的潜在作用是调节儿童骨肉瘤血管生成的一个有吸引力的概念。
